Anti-hIFN-β Neutralizing mAb

Neutralizing IgG monoclonal antibody to human interferon-beta

Neutralizing monoclonal antibody against human IFN-β

Anti-hIFN-β-IgG (clone 10B10) is a monoclonal antibody for human interferon β (hIFN-β). This antibody has been produced in hybridomas and purified by affinity chromatography.
Anti-hIFN-β-IgG has been selected for its ability to efficiently neutralize the biological activity of hIFN-β. IFN-β is an important anti-viral cytokine that also has anti-proliferative and immunomodulatory functions [1, 2].

More details

Key features:

• Reacts with hIFN-β
• Provided azide-free
• Each lot is functionally tested

References:

1. Schreiber G. 2017. The molecular basis for differential type I interferon signaling. J. Biol. Chem. 292:7285-94.
2. McNab F. et al., 2015. Type I interferons in infectious disease. Nat Rev Immunol. 15(2):87-103.

Figures

Increasing concentrations of Anti-hIFN-β-IgG were incubated for 30 minutes with the recombinant cytokine hIFN-β (0.3 U/ml) prior to the addition of HEK-Blue™ IFN-α/β cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage (%) of neutralization.

Specifications

Target: natural and recombinant human interferon-beta (IFN-β)

Source: Hybridoma cells

Clone: 10B10

Isotype: Mouse IgG2a, kappa

Control: Mouse IgG2a Control

Immunogen: Human IFN-β protein expressed in Swiss mice following DNA immunization

Formulation: 0.2 µm filtered solution in sodium phosphate buffer with saccharose, glycine and stabilizing agents

Applications: Neutralization/block

Quality control:

• This product has been validated for neutralization using cellular assays.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Contents

• 3 x 100 μg purified anti-hIFN-β-IgG antibody, provided azide-free and lyophilized

Product is shipped at room temperature.

Store lyophilized antibody at -20 °C.

Details

Type I interferons, in particular interferon-alpha (IFN-α) and interferon beta (IFN-β), play a vital role in host resistance to viral infections [1, 2]. The type I IFN family is a multi-gene cytokine family that encodes 13 partially homologous IFN-α subtypes in humans (14 in mice), a single IFN-β, and several poorly defined single gene products (IFN-ɛ, IFN-τ, IFN-κ, IFN-ω, IFN-δ, and IFN-ζ) [1, 2].  IFN-α and IFN-β are the best-defined and most broadly expressed type I IFNs [2].

IFN-β and all of the IFN-α subtypes bind to a heterodimeric transmembrane receptor composed of the subunits IFNAR1 and IFNAR2 which are associated with the tyrosine kinases Tyk2 and Jak1 (Janus kinase 1) respectively. These kinases phosphorylate STAT1 and STAT2 which then dimerize and interact with IFN regulatory factor 9 (IRF9), leading to the formation of the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression. 

1. Schreiber G. 2017. The molecular basis for differential type I interferon signaling. J. Biol. Chem. 292:7285-94.
2. McNab F. et al., 2015. Type I interferons in infectious disease. Nat Rev Immunol. 15(2):87-103.